The Use of a Single-Pill Calcium Channel Blocker/Statin Combination in the Management of Hypertension and Dyslipidemia: A Randomized, Placebo-Controlled, Multicenter Study
Version of Record online: 5 JAN 2009
© 2009 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 11, Issue 1, pages 22–30, January 2009
How to Cite
Neutel, J. M., Bestermann, W. H., Dyess, E. M., Graff, A., Kursun, A., Sutradhar, S. and Yunis, C. (2009), The Use of a Single-Pill Calcium Channel Blocker/Statin Combination in the Management of Hypertension and Dyslipidemia: A Randomized, Placebo-Controlled, Multicenter Study. The Journal of Clinical Hypertension, 11: 22–30. doi: 10.1111/j.1751-7176.2008.00058.x
- Issue online: 5 JAN 2009
- Version of Record online: 5 JAN 2009
- Manuscript received June 30, 2008; revised October 27, 2008; accepted November 5, 2008
- 5Rationale for multiple risk intervention: the need to move from theory to practice. Vasc Health Risk Manag. 2007;3:985–997..
- 13on behalf of the JEWEL Study Group. Multiple risk intervention with a single-pill combination (amlodipine/atorvastatin) helps patients to attain recommended target levels for blood pressure and lipids (The JEWEL Program). J Clin Hypertens. 2006;8:455.
- 16National Cholesterol Education Program of the National Institutes of Health National Heart Lung and Blood Institute. Spreadsheet-Based 10-Year Risk Assessment Tool http://hin.nhlbi.nih.gov/atpiii/riskcalc.htm. Accessed December 17, 2008.
- 17National Heart Lung, and Blood Institute. Cardiovascular Disease Risk Reduction, Adults Cholesterol Guidelines Update, ATP IV Hypertension Guidelines Update, JNC 8 Obesity Guidelines Update. 2008. http://www.nhlbi.nih.gov/guidelines/cvd_adult/background.htm. Accessed December 17, 2008.